Hims & Hers Health stock price forecast: $22.50 support as HIMS trades down

Traders Union
All News
Financial News
Hims & Hers Health slides 1.08% today

Highlights

Hims & Hers Health launched Canada's first generic semaglutide after Novo Nordisk's patent expiry, accessing a previously restricted GLP-1 market segment.
The company raised $350 million via 0% convertible notes due 2032, securing capital to expand its health platform and GLP-1 offerings.
Shares trade below major moving averages with sustained seller control; next five-day price range expected between $22.50 and $24.50, bias remains bearish.

New generic launch and convertible notes weigh on sentiment shift

Hims & Hers Health launched its generic version of semaglutide in Canada following the expiry of Novo Nordisk's patent, enabling access to a previously restricted segment of the GLP-1 market. This move was supported by Health Canada's approval of the first generic semaglutide products in a G7 country, allowing the company to rapidly commercialize the therapy and expand its product portfolio. In addition, Hims & Hers Health priced a $350 million offering of 0% convertible senior notes due 2032, providing additional capital for scaling its health platform and GLP-1 partnerships, though price action has remained under broader selling pressure.

Weak momentum persists as resistance and oversold signals converge

Technically, HIMS faces resistance at the Ichimoku Kijun level of $26.70, with further obstacles at the MA-20 ($25.79), MA-50 ($24.25), and MA-200 ($34.94). Momentum indicators on the daily chart remain weak: both the MACD and RSI are flashing sell signals, while ADX indicates the trend lacks clear strength. The CCI is also in sell territory, and the Bull/Bear Power (BBP) points to an oversold condition. The daily price is fluctuating in a moderate range between $23.31 and $24.50; conflicting intraday reads are present, with a neutral Stoch RSI and a bearish Awesome Oscillator aligning with short-term downside momentum.

Limited upside seen as volatility bands constrain breakout risk

Over the next five trading days, HIMS is expected to fluctuate within a typical volatility band of $22.50 to $24.50 relative to current levels. The probability of a breakout to the upside is low, with any sustained bullish reversal likely requiring a decisive move above resistance at $26.70. The base scenario favors continued sideways action within this range, while a breakdown below $22.50 could extend the prevailing downtrend if selling pressure intensifies.

Anton Kharitonov, analyst at Traders Union, sees Hims & Hers Health's generic semaglutide launch as a strong move, but technicals remain negative. Price sits below all key moving averages, and momentum stays weak despite positive business developments. Base case is for HIMS to remain sideways in the $22.50 to $24.50 range with a low chance of reversal until $26.70 is reclaimed. "With persistent selling pressure and weak momentum, I see little edge for buyers unless key resistance levels are broken convincingly."

Earlier, analysts noted that Hims & Hers Health was experiencing persistent bearish momentum with downside risks dominating the outlook. The current technical setup continues to favor rangebound activity and highlights $22.50 as a key downside level to monitor, where a decisive break could intensify short-term selling pressure.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.